Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMXSEHF)

Drug Name

Y-39983 Drug Info

Synonyms

RKI-983; SNJ-1656; ROCK inhibitors, Mitsubishi Tanabe Pharma/Senju/Novartis; Rho-associated protein kinase inhibitors, Mitsubishi Tanabe Pharma/Senju/Novartis

Indication

Disease Entry	ICD 11	Status	REF
Glaucoma/ocular hypertension	9C61	Phase 1/2	[1]

Cross-matching ID

PubChem CID: 9810884
ChEBI ID: CHEBI:91412
CAS Number: CAS 199433-58-4
TTD Drug ID: DMXSEHF

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Rho-associated protein kinase (ROCK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Netarsudil	DM0LPI9	Open-angle glaucoma	9C61	Approved	[3]
Ximelegatran	DMU8ANS	Myocardial infarction	BA41-BA43	Approved	[4]
Roclatan	DMVQ5X1	Glaucoma/ocular hypertension	9C61	Phase 3	[5]
AR-12286	DM5TC43	Glaucoma/ocular hypertension	9C61	Phase 2	[6]
AMA-76	DMBWNX5	Glaucoma/ocular hypertension	9C61	Phase 2	[7]
Cethrin	DMD3XMW	Spinal cord injury	ND51.2	Phase 1/2	[8]
STM 434	DMDF29A	Ovarian cancer	2C73	Phase 1	[9]
AT13148	DMYIPKJ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]
Hexahydro azepinone derivative 1	DMC1ZIX	N. A.	N. A.	Patented	[9]
Isoquinoline sulfonyl derivative 2	DMT5E7M	N. A.	N. A.	Patented	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Rho-associated protein kinase (ROCK)	TTMQO60	NOUNIPROTAC	Modulator	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT00846989) Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension. U.S. National Institutes of Health.
2	Effects of Y-39983, a selective Rho-associated protein kinase inhibitor, on blood flow in optic nerve head in rabbits and axonal regeneration of retinal ganglion cells in rats.Curr Eye Res. 2011 Oct;36(10):964-70.
3	Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes. J Glaucoma. 2015 Jan;24(1):51-4.
4	Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol Pharmacol. 2000 May;57(5):976-83.
5	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
6	Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension. Am J Ophthalmol. 2011 Nov;152(5):834-41.e1.
7	AMA0076, a novel, locally acting Rho kinase inhibitor, potently lowers intraocular pressure in New Zealand white rabbits with minimal hyperemia. Invest Ophthalmol Vis Sci. 2014 Feb 18;55(2):1006-16.
8	A phase I/IIa clinical trial of a recombinant Rho protein antagonist in acute spinal cord injury. J Neurotrauma. 2011 May;28(5):787-96.
9	Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515.
10	Company report (Astex)